JGC
VIRX

J. Goldman & Co’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

J. Goldman & Co’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,905
Closed -$980K – 345
2015
Q1 		$980K Buy
+1,905
New +$961K 0.06% 227
2014
Q4 		– Sell
-417
Closed -$625K – 295
2014
Q3 		$625K Sell
417
-488
-54% -$707K 0.04% 236
2014
Q2 		$1.24M Hold
905
– – 0.09% 175
2014
Q1 		$1.26M Buy
+905
New +$1.05M 0.09% 195

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

J. Goldman & Co's VIRX Position: Q3 2014 in Review

J. Goldman & Co sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2014, closing a stake of 417 shares — an estimated $604K sold.

J. Goldman & Co first reported a position in VIRX in Q2 2014 and held it in 1 quarter. The position peaked at $570K in Q2 2014. 104 funds tracked by Wall St. Rank hold VIRX as of Q3 2014.

  • J. Goldman & Co reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • J. Goldman & Co sold 417 Viracta Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $604K.
  • J. Goldman & Co first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • J. Goldman & Co's Viracta Therapeutics, Inc. Common Stock position peaked at $570K in Q2 2014.
  • 104 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2014.

Based on J. Goldman & Co's 13F filing for Q3 2014, filed 14 Nov 2014.